-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACI-35030 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACI-35030 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACI-35030 in Alzheimer's Disease Drug Details: ACI-35.030 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACI-35030 in Tauopathies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACI-35030 in Tauopathies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACI-35030 in Tauopathies Drug Details: ACI-35.030 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-547 in Uremic (Renal) Pruritus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Uremic (Renal) Pruritus Drug Details: EP-547 is under developmant...
-
Product Insights
Lewy Body Dementia – Drugs In Development, 2023
Global Markets Direct’s, ‘Lewy Body Dementia - Drugs In Development, 2023’, provides an overview of the Lewy Body Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lewy Body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tauopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Tauopathies - Drugs In Development, 2023’, provides an overview of the Tauopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tauopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2023
Global Markets Direct’s, ‘Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2023’, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Down Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Down Syndrome - Drugs In Development, 2023’, provides an overview of the Down Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Contrast Agents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Contrast Agents Pipeline Market Report Overview The Contrast Agents pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Positron Emitting Tomography Contrast Agents ·       Magnetic Resonance Imaging (MRI) Contrast Agents ·       Gadolinium-based MRI Contrast Agents...